Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Atkinson

Showing results (51-60 of 126) with videos related to

Pageof 13
Sort By:
Journal of Surgical Oncology|May 29, 2018
Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagusEls Visser, David Edholm, B Mark Smithers, et al.
Frontiers in Neurology|March 10, 2023
Case series: Immune checkpoint inhibitor-induced transverse myelitisSophie Chatterton, Shuo Xi, Jessica Xi Jia, et al.
JACC. Clinical Electrophysiology|May 16, 2018
Temporal Stability of Rotors and Atrial Activation Patterns in Persistent Human Atrial Fibrillation: A High-Density Epicardial Mapping Study of Prolonged RecordingsTomos E Walters, Geoffrey Lee, Gwilym Morris, et al.
Immunotherapy|May 3, 2023
Health-related quality of life in patients with melanoma brain metastases treated with immunotherapyJake R Thompson, Julia Lai-Kwon, Rachael L Morton, et al.
The Journal of Molecular Diagnostics : JMD|August 6, 2023
Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative MelanomaLauren G Aoude, Sandra Brosda, Jessica Ng, et al.
Scientific Reports|October 20, 2020
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsLauren G Aoude, Vanessa F Bonazzi, Sandra Brosda, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
Journal for Immunotherapy of Cancer|May 8, 2020
Efficacy of immune checkpoint inhibitors for in-transit melanomaEmilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Pageof 13

Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Journal of Surgical Oncology|May 29, 2018
Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagusEls Visser, David Edholm, B Mark Smithers, et al.
Frontiers in Neurology|March 10, 2023
Case series: Immune checkpoint inhibitor-induced transverse myelitisSophie Chatterton, Shuo Xi, Jessica Xi Jia, et al.
JACC. Clinical Electrophysiology|May 16, 2018
Temporal Stability of Rotors and Atrial Activation Patterns in Persistent Human Atrial Fibrillation: A High-Density Epicardial Mapping Study of Prolonged RecordingsTomos E Walters, Geoffrey Lee, Gwilym Morris, et al.
Immunotherapy|May 3, 2023
Health-related quality of life in patients with melanoma brain metastases treated with immunotherapyJake R Thompson, Julia Lai-Kwon, Rachael L Morton, et al.
The Journal of Molecular Diagnostics : JMD|August 6, 2023
Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative MelanomaLauren G Aoude, Sandra Brosda, Jessica Ng, et al.
Scientific Reports|October 20, 2020
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsLauren G Aoude, Vanessa F Bonazzi, Sandra Brosda, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
Journal for Immunotherapy of Cancer|May 8, 2020
Efficacy of immune checkpoint inhibitors for in-transit melanomaEmilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, et al.
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Pageof 13